Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.55 |
| ▸ | PPARD | Q03181 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | VNN1 | O95497 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24060169 | 0.83 | PPARD (0.55) | PPARAPPARDPPARGEPHX2ROCK2 | |
| SCHEMBL24268607 | 0.79 | SCN3A (0.43) | PPARAPPARDPPARGEPHX2ROCK2 | |
| SCHEMBL20272048 | 0.79 | EPHX2 (0.52) | PPARAPPARDPPARGEPHX2NR1H4 | |
| SCHEMBL27220646 | 0.78 | PPARG (0.56) | PPARAPPARDPPARGEPHX2NR1H4 | |
| SCHEMBL29538410 | 0.75 | MAPK8 (0.39) | PPARAPPARDPPARGEPHX2ROCK2 | |
| SCHEMBL24060151 | 0.75 | MAPK8 (0.39) | PPARAPPARDPPARGEPHX2ROCK2 | |
| SCHEMBL27188864 | 0.74 | EPHX2 (0.52) | PPARAPPARDPPARGEPHX2NR1H4 | |
| SCHEMBL29896128 | 0.74 | EPHX2 (0.52) | PPARAPPARDPPARGEPHX2NR1H4 | |
| SCHEMBL24268595 | 0.74 | PPARD (0.47) | PPARAPPARDPPARGEPHX2ROCK2 | |
| SCHEMBL21045704 | 0.73 | AR (0.42) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637418-B2 | Heterocyclic compounds as antagonist of NMDA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-26 | — | — | US | disclosed |
| US-20220089525-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089525-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2B, GRIN2A | PPARA 1157/4885PPARD 1074/4885PPARG 1014/4885 |
| US-12637418-B2 | Heterocyclic compounds as antagonist of NMDA | GRIN1, GRIN3A, GRIN2A | PPARA 1554/4885PPARD 2118/4885PPARG 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.